Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687622 · ClinicalTrials.gov registry record · Phase 1
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT00687622: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00687622 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 206 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00687622, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Part 3 will determine a range of effective doses.
Interventions
- DRUG GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2008-07-28 |
| Est. Completion | 2011-11-08 |
| Phase | Phase 1 |
What the finished NCT00687622 record still lists
NCT00687622 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (243% higher).
The record links to 0 conditions, and to 1 intervention - of which GSK1120212 is the first listed.
NCT00687622 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00687622 about?
NCT00687622 is a clinical study titled "Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma". MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Pa...
What is the current status of trial NCT00687622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2008-07-28. Estimated completion is 2011-11-08.
What interventions are being tested in trial NCT00687622?
The interventions under investigation include: GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT00687622?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00687622's enrollment target sits among peer trials
206 253rd of 2000 higher than 1,748 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI